{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T20:38:11Z","timestamp":1782851891396,"version":"3.54.5"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Camurus AB"},{"DOI":"10.13039\/100006662","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203308"],"award-info":[{"award-number":["NIHR203308"]}],"id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000276","name":"Department of Health and Social Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Our aim was to explore the effect of a single subcutaneous dose of CAM2043, a novel extended-release subcutaneous formulation of treprostinil, on finger temperature in patients with SSc-related RP.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was an exploratory, open-label, single-dose Phase 2 trial. Ten female patients (median age 54.0 years) attended on six occasions: screening, baseline (day 1), days 2, 3, 8 and 15. On day 1, patients received a single subcutaneous injection of 2.5\u2009mg CAM2043. A standard cold challenge test of the hands was performed pre-dose and at 3, 6, 24, 72, 168 and 336\u2009h post-dose, with temperature response over the subsequent 15\u2009min measured by infrared thermography. The primary end point was the mean change in area under the temperature-time curve (AUCtherm) for rewarming (eight fingers) at 6\u2009h vs baseline.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>AUCtherm increased 6\u2009h post-dose (mean increase 192.7\u00b0C\u00d7sec [95% CI: \u2212727.1, 1112.6]) and was significantly greater at 24\u2009h than at baseline (mean increase 1175.8\u00b0C\u00d7sec [95% CI: 127.3, 2224.3]), returning to baseline values by day 15. Maximum temperature after rewarming increased significantly from baseline at 24\u2009h, by 1.4\u00b0C (95% CI: 0.1, 2.7). Mean (S.D.) Raynaud\u2019s Condition Score (3.7 [1.3] units at baseline) improved significantly post-dosing, including day 8 (mean reduction 1.6 units [95% CI: \u22122.68, \u22120.52]). Adverse events were reported by all 10 patients: all reported erythema and pain at the injection site.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The positive outcome indicates that CAM2043 could be further investigated in clinical trials of RP.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>www.clinicaltrialsregister.eu\/, EudraCT number 2019\u2013002444-24.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf291","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T12:27:39Z","timestamp":1748521659000},"page":"5498-5503","source":"Crossref","is-referenced-by-count":3,"title":["An exploratory trial of a single dose of CAM2043 (treprostinil subcutaneous depot) in SSc-related RP"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4941-7926","authenticated-orcid":false,"given":"Ariane L","family":"Herrick","sequence":"first","affiliation":[{"name":"Centre for Musculoskeletal Research, The University of Manchester, Manchester Academic Health Science Centre , Manchester,","place":["UK"]},{"name":"Rheumatology Department, Northern Care Alliance NHS Foundation Trust , Salford,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9244-2882","authenticated-orcid":false,"given":"Andrea","family":"Murray","sequence":"additional","affiliation":[{"name":"Centre for Musculoskeletal Research, The University of Manchester, Manchester Academic Health Science Centre , Manchester,","place":["UK"]},{"name":"Rheumatology Department, Northern Care Alliance NHS Foundation Trust , Salford,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6245-2721","authenticated-orcid":false,"given":"Graham","family":"Dinsdale","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Northern Care Alliance NHS Foundation Trust , Salford,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Manning","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Northern Care Alliance NHS Foundation Trust , Salford,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chukwuma","family":"Chukwu","sequence":"additional","affiliation":[{"name":"Clinical Research Facility, Northern Care Alliance NHS Foundation Trust , Salford,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Alvarez Fernandez","sequence":"additional","affiliation":[{"name":"Clinical Development, Camurus AB , Lund,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrika","family":"Axling","sequence":"additional","affiliation":[{"name":"Clinical Development, Camurus AB , Lund,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R","family":"Seibold","sequence":"additional","affiliation":[{"name":"Scleroderma Research Consultants LLC , Aiken, SC,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0080-4490","authenticated-orcid":false,"given":"Fredrik","family":"Tiberg","sequence":"additional","affiliation":[{"name":"Clinical Development, Camurus AB , Lund,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"key":"2025100315125572600_keaf291-B1","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/annrheumdis-2011-200742","article-title":"Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database","volume":"71","author":"Meier","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2025100315125572600_keaf291-B2","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1093\/rheumatology\/kev002","article-title":"Prediction and impact of attacks of Raynaud\u2019s phenomenon, as judged by patient perception","volume":"54","author":"Hughes","year":"2015","journal-title":"Rheumatology"},{"key":"2025100315125572600_keaf291-B3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.semarthrit.2016.02.005","article-title":"Impaired quality of life in systemic sclerosis and patient perception of the disease: a large international survey","volume":"46","author":"Frantz","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2025100315125572600_keaf291-B4","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s41584-020-0386-4","article-title":"Raynaud phenomenon and digital ulcers in systemic sclerosis","volume":"16","author":"Hughes","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"2025100315125572600_keaf291-B5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/1759720X17740074","article-title":"Evidence-based management of Raynaud\u2019s phenomenon","volume":"9","author":"Herrick","year":"2017","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2025100315125572600_keaf291-B6","doi-asserted-by":"crossref","first-page":"e2376","DOI":"10.1016\/S2665-9913(19)30079-7","article-title":"Comparative efficacy and safety of treatments for secondary Raynaud\u2019s phenomenon: a systematic review and network meta-analysis of randomised trials","volume":"1","author":"Khouri","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"2025100315125572600_keaf291-B7","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1093\/rheumatology\/keae394","article-title":"The 2024 British Society for Rheumatology guideline for management of systemic sclerosis","volume":"63","author":"Denton","year":"2024","journal-title":"Rheumatology"},{"key":"2025100315125572600_keaf291-B8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/ard-2024-226430","article-title":"EULAR recommendations for the treatment of systemic sclerosis: 2023 update","volume":"84","author":"Del Galdo","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"2025100315125572600_keaf291-B9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/0003-4819-120-3-199402010-00004","article-title":"Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study","volume":"120","author":"Wigley","year":"1994","journal-title":"Ann Intern Med"},{"key":"2025100315125572600_keaf291-B10","first-page":"CD000953","article-title":"Iloprost and cisaprost for Raynaud\u2019s phenomenon in progressive systemic sclerosis","volume":"1998","author":"Pope","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"2025100315125572600_keaf291-B11","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1246\/cl.2012.1090","article-title":"Phase behavior, functions, and medical applications of soy phosphatidylcholine and diglyceride lipid compositions","volume":"41","author":"Tiberg","year":"2012","journal-title":"Chem Lett"},{"key":"2025100315125572600_keaf291-B12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1773-2247(11)50009-7","article-title":"Drug delivery applications of non-lamellar liquid crystalline phases and nanoparticles","volume":"21","author":"Tiberg","year":"2011","journal-title":"J Drug Deliv Sci Technol"},{"key":"2025100315125572600_keaf291-B13","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/art.40457","article-title":"A multicenter study of the validity and reliability of responses to hand cold challenge as measured by laser speckle contrast imaging and thermography: outcome measures for systemic sclerosis-related Raynaud\u2019s phenomenon","volume":"70","author":"Wilkinson","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025100315125572600_keaf291-B14","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/art.10486","article-title":"Measuring disease activity and functional status in patients with scleroderma and Raynaud\u2019s phenomenon","volume":"46","author":"Merkel","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2025100315125572600_keaf291-B15","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2025100315125572600_keaf291-B16","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1136\/ard.2009.107706","article-title":"The minimally important difference and patient acceptable symptom state for the Raynaud\u2019s condition score in patients with Raynaud\u2019s phenomenon in a large randomised controlled clinical trial","volume":"69","author":"Khanna","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2025100315125572600_keaf291-B17","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1183\/09031936.06.00044406","article-title":"Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil","volume":"28","author":"Barst","year":"2006","journal-title":"Eur Respir J"},{"key":"2025100315125572600_keaf291-B18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S2213-2600(18)30367-9","article-title":"Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial","volume":"7","author":"Sadushi-Kolici","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2025100315125572600_keaf291-B19","year":"2020"},{"key":"2025100315125572600_keaf291-B20","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/art.1780350614","article-title":"Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis","volume":"35","author":"Wigley","year":"1992","journal-title":"Arthritis Rheum"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf291\/63399914\/keaf291.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/10\/5498\/63399914\/keaf291.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/10\/5498\/63399914\/keaf291.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:13:06Z","timestamp":1759518786000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/10\/5498\/8152875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":20,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,5,29]]},"published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf291","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,5,29]]}}}